Biosecure ID – Unlocking the Potential of Molecular Testing

🟢 Seed Round Open · $1.5M (£1M) Target · SEIS/EIS Eligible · HMRC Advance Assurance Confirmed

Biosecure ID® · Macclesfield, UK · Est. 2024

Unlocking the potential
of molecular testing
for a better world

A forensic biotechnology and biometric identity company — building the end-to-end workflow, the innovation platform, and the partnerships that bring rapid, affordable DNA identification to laboratories worldwide.

Request investor pack Explore workflow →

ISO 18385:2016 Forensic Grade

Alderley Park R&D

UK Innovation Ecosystem

Companies House 15571838

Live programme metrics Seed Round open

$1.5M (£1M)

Seed Round target · Early commitments secured

<1 day

DNA turnaround with Vellixis vs 14 days today

£300M

Human ID market opportunity

↑80%

Sperm recovery improvement — published study

🛡️ SEIS/EIS eligible · HMRC Advance Assurance confirmed for up to £1M Learn more →

💰

Investors & Fund Managers

Seed Round open now. SEIS/EIS eligible. Early commitments secured. HMRC Advance Assurance confirmed.

Request investor pack →

🔬

Forensic Laboratories

End-to-end workflow solutions from sample collection through STR, NGS, and data analysis. ISO 18385 compliant.

Explore workflow →

🤝

Partners & Co-developers

Value-added reselling, co-development partnerships, customisation, and population-scale programme delivery.

Explore collaboration →

A global problem,
urgently unmet

>3 mo.

Average time from sample collection to DNA result in a sexual assault case

2.5M

Rape cases reported globally per year — only 20% receive DNA analysis

50%+

Of forensic samples yield no usable results with today's manual lab process

$25B

Applied genetic testing market — growing at double-digit CAGR, ripe for disruption

Innovation Programme

Vellixis™

Automated Differential Extraction · SpermX™ Nanofiber

<1 day

DNA profile from sexual assault evidence
vs 14 days with current methods

Vellixis Nano Active

Vellixis Capture Planned

Vellixis RareCell Vision

The Vellixis Programme

From weeks to hours.
Then hours to minutes.

The bottleneck in forensic DNA is not analysis — it is the manual, error-prone sample preparation step that precedes it. The Vellixis Programme automates this with SpermX™ Nanofiber technology, delivering DNA profiles in under one day from sexual assault evidence.

Three generations of platform development take Biosecure ID from forensic casework into clinical oncology (CTC/cfDNA) and integrated NGS — a £2B applied genomics opportunity built on a single technology stack.

£20M

Serviceable entry market — Vellixis Nano

TRL 6

Target across sub-components — 18-month incubation

↑80%

SpermX™ recovery vs conventional methods*

3 Gen.

Forensic → Clinical → NGS roadmap

Explore Vellixis → Invest in this →

* Interlaboratory comparison study. Forensic Sciences, Dec 2023, DOI: 10.3390/forensicsci3040043

Workflow Platform

From sample to intelligence —
end-to-end